人類生物檢體市場規模、佔有率和成長分析：檢體類型、應用、最終用途、儲存類型、採購類型、地區和產業預測，2026-2033年

2024年全球人類生物檢體市場價值為46億美元，預計將從2025年的50億美元成長到2033年的97.5億美元。預測期（2026-2033年）的複合年成長率預計為8.7%。

全球人類生物檢體市場涵蓋組織、血液、細胞和DNA等生物材料的採集、處理、儲存和分發，這些材料對於研發、診斷和治療開發至關重要。轉化研究和精準醫療的需求不斷成長，對高品質、帶註釋的樣本的需求也隨之增加，這有助於加速藥物發現和改善患者分層。該市場正從區域生物樣本庫轉向互聯互通的資料庫，凸顯了整合臨床數據和樣本的重要性。對可互通資料庫和知情同意平台的投入不斷增加，促進了醫院和國家生物樣本庫之間的合作。此外，區塊鏈技術增強了可追溯性，提供了不可篡改的檢體來源記錄，提高了樣本的可發現性和提供者的可信度，同時簡化了分散市場中的監管合規流程。

全球人類生物檢體市場促進因素

對生物標記發現和轉化研究的日益重視顯著增加了對高品質、高註釋的人體組織和體液檢體的需求，從而擴大了樣本採集、處理和儲存服務的市場。研究機構和行業相關人員正在尋求各種疾病特異性樣本，用於檢驗研究對象和評估生物標記的有效性。為了應對這一不斷成長的需求，生物樣本庫和商業供應商正在提升服務水準並建立夥伴關係。同時，用於制定標準化通訊協定、改善知情同意流程和簡化物流的投資也大幅增加，所有這些都在建立一個強大且永續的生態系統，並推動市場持續成長。

全球人類生物檢體市場的限制因素

全球人類生物檢體市場面臨許多阻礙因素，包括法規結構的差異、不同的知情同意要求以及關於樣本進出口和再利用的不統一指導方針。這造成了複雜的合規環境，阻礙了市場發展。各機構在尋求跨國合作和將生物樣本衍生產品商業化時面臨法律上的模糊地帶，導致籌資策略保守，並限制了關鍵材料的共用。此外，管理各種倫理核准和資料保護條例的需求增加了行政負擔，延長了計劃週期，並阻礙了部分相關人員與外部樣本提供者的合作，最終抑制了市場的成長潛力。

全球人類生物檢體市場趨勢

全球人類生物檢體市場正日益受到整合生物樣本庫網路興起的影響。這些網路促進了不同機構間更緊密的合作，推動了高效的樣本共用、標準化的通訊協定以及對各種樣本庫的更便捷存取。透過強調互通性和統一的知情同意框架，這些網路有效地減少了重複工作，擴大了研究人群，並促進了多中心合作研究，從而加速了轉化研究的進程。此外，平台和實驗室資訊系統（LIS）的整合，以及標準化的元資料收集，顯著提高了檢體的可追溯性和品質保證。這種合作框架為學術機構、臨床機構和商業機構之間建立可擴展的夥伴關係關係奠定了基礎，最終推動了全球診斷、治療方法和精準醫療的發展。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

市場考察

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場吸引力指數
• PESTEL 分析
• 監理情勢

全球人類生物檢體市場規模：按檢體類型和複合年成長率分類（2026-2033 年）

• 組織檢體
• 生物液體
• 細胞材料
• 核酸

全球人類生物檢體市場規模：按應用和複合年成長率分類（2026-2033 年）

• 癌症研究
• 藥物發現
• 診斷
  • 生物標記發現
• 轉化研究
  • 基因組研究
• 精準醫療
• 感染疾病研究
  • COVID-19
  • HIV
  • 結核
• 神經系統和心血管系統檢查

全球人類生物檢體市場規模：依最終用途和複合年成長率分類（2026-2033 年）

• 製藥公司
• 生技公司
• CRO（受託研究機構）
• 學術機構
• 醫院和生物樣本庫
• 診斷檢查室
• 政府機構
• 非營利組織

全球人類生物檢體市場規模：按儲存類型和複合年成長率分類（2026-2033 年）

• 冷藏
  • -80°C 或液態氮(LN2)
  • 低溫儲存
  • 液態氮（-196 度C）
• 室溫保存
• 福馬林固定與保存

全球人類生物檢體市場規模：依採購類型和複合年成長率分類（2026-2033 年）

• 正向收集
• 過去的檢體

全球人類生物檢體市場規模：按地區和複合年成長率分類（2026-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要企業簡介

• BioIVT
• Precision for Medicine
• Conversant Bio
• Indivumed GmbH
• REPROCELL Inc.
• US Biolab Corporation, Inc.
• Biobank Graz
• ProteoGenex Inc.
• Seracare Life Sciences
• Celdara Medical
• Coriell Institute for Medical Research
• HudsonAlpha Institute for Biotechnology
• LabCorp
• Bionano Genomics
• Mayo Clinic Biobank
• Viacyte
• QIAGEN
• Asterand Bioscience
• Global Bioclinical
• Omnigenics

結論與建議

Global Human Biospecimens Market size was valued at USD 4.6 Billion in 2024 and is poised to grow from USD 5.0 Billion in 2025 to USD 9.75 Billion by 2033, growing at a CAGR of 8.7% during the forecast period (2026-2033).

The global human biospecimens market involves the collection, processing, storage, and distribution of biological materials, including tissues, blood, cells, and DNA, essential for research, diagnostics, and therapy development. The growing need for high-quality annotated specimens is propelled by the demands of translational research and precision medicine, facilitating drug discovery and improving patient stratification. This market is transitioning from local biobanks to interconnected repositories, emphasizing the importance of integrating clinical data with specimens. Investments in interoperable databases and consent platforms are on the rise, fostering collaborations among hospitals and national biobanks. Additionally, blockchain technology can enhance traceability, providing an immutable record of specimen provenance, thereby improving discoverability and donor trust while streamlining regulatory compliance in a fragmented market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Human Biospecimens market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Human Biospecimens Market Segments Analysis

Global human biospecimens market is segmented by specimen type, application, end use, storage type, procurement type and region. Based on specimen type, the market is segmented into Tissue Specimens, Biofluids, Cellular Material and Nucleic Acids. Based on application, the market is segmented into Cancer Research, Drug Discovery, Diagnostics, Translational Research, Precision Medicine, Infectious Disease Studies and Neurology and Cardiovascular Research. Based on end use, the market is segmented into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Academic Institutes, Hospitals and Biobanks, Diagnostic Laboratories, Government Organizations and Non-Profit Organizations. Based on storage type, the market is segmented into Cold Storage, Ambient Storage and Formalin-Fixed Storage. Based on procurement type, the market is segmented into Prospective Collection and Retrospective Samples. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Human Biospecimens Market

The growing emphasis on biomarker discovery and translational research has significantly increased the demand for high-quality, well-annotated human tissue and fluid specimens, thus broadening the market for collection, processing, and storage services. Research organizations and industry stakeholders are seeking diverse, disease-specific samples to validate research targets and evaluate biomarker efficacy. This heightened demand has prompted biobanks and commercial suppliers to enhance their services and forge partnerships. In response, there has been a surge in investment aimed at developing standardized protocols, refining consent processes, and improving logistics, all of which contribute to a robust and sustainable ecosystem that drives continued market expansion.

Restraints in the Global Human Biospecimens Market

The Global Human Biospecimens market faces considerable constraints due to a patchwork of regulatory frameworks, differing consent mandates, and uneven guidelines for the import, export, and reuse of samples. This creates a complex compliance landscape that hampers market development. Organizations encounter legal ambiguities when pursuing cross-border partnerships or commercializing products derived from biospecimens, resulting in conservative procurement strategies and restricted sharing of critical materials. Additionally, the necessity to manage varied ethical approvals and data protection regulations adds to administrative burdens, prolonging project timelines and deterring some stakeholders from collaborating with external sample providers, ultimately stalling the market's growth potential.

Market Trends of the Global Human Biospecimens Market

The Global Human Biospecimens market is increasingly influenced by the emergence of integrated biobank networks, which facilitate enhanced collaboration among various institutions. These networks promote streamlined sample sharing, standardized protocols, and improved access to a diverse range of specimen repositories. By emphasizing interoperability and unified consent frameworks, they effectively minimize duplication, broaden research cohorts, and encourage multi-center studies that expedite translational research. Furthermore, the integration of platforms with laboratory information systems and standardized metadata capture significantly boosts specimen traceability and quality assurance. This collaborative framework paves the way for scalable partnerships among academic, clinical, and commercial entities, ultimately advancing the development of diagnostics, therapeutics, and precision medicine globally.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Human Biospecimens Market Size by Specimen Type & CAGR (2026-2033)

• Market Overview
• Tissue Specimens
• Biofluids
• Cellular Material
• Nucleic Acids

Global Human Biospecimens Market Size by Application & CAGR (2026-2033)

• Market Overview
• Cancer Research
• Drug Discovery
• Diagnostics
  • Biomarker Discovery
• Translational Research
  • Genomic Research
• Precision Medicine
• Infectious Disease Studies
  • COVID-19
  • HIV
  • TB
• Neurology and Cardiovascular Research

Global Human Biospecimens Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Pharmaceutical Companies
• Biotechnology Companies
• Contract Research Organizations
• Academic Institutes
• Hospitals and Biobanks
• Diagnostic Laboratories
• Government Organizations
• Non-Profit Organizations

Global Human Biospecimens Market Size by Storage Type & CAGR (2026-2033)

• Market Overview
• Cold Storage
  • -80°C or LN2
  • Cryogenic
  • Liquid Nitrogen (-196°C)
• Ambient Storage
• Formalin-Fixed Storage

Global Human Biospecimens Market Size by Procurement Type & CAGR (2026-2033)

• Market Overview
• Prospective Collection
• Retrospective Samples

Global Human Biospecimens Market Size & CAGR (2026-2033)

• North America (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • US
  • Canada
• Europe (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specimen Type, Application, End Use, Storage Type, Procurement Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• BioIVT
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision for Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Conversant Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indivumed GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• REPROCELL Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• US Biolab Corporation, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biobank Graz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ProteoGenex Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seracare Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celdara Medical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Coriell Institute for Medical Research
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• HudsonAlpha Institute for Biotechnology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LabCorp
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bionano Genomics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mayo Clinic Biobank
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viacyte
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asterand Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Bioclinical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Omnigenics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations